



Medicines
Optimisation Update
Issue April 2023

To contact NHS BSW ICB Medicines Optimisation Team:

□ bswicb.prescribing@nhs.net

Website: https://bswtogether.org.uk/medicines/

BSW Area Prescribing Committee (APC) Updates

All recent decisions made by the BSW APC can be read in full <u>here</u> or in the newsfeed of the <u>BSWformulary homepage</u>

New and Updated Shared Care Agreements and Prescribing Guidance

- NEW BSW SCA for Guanfacine for the treatment of ADHD in Adults. Used in line with NICE NG87 as a third-line option (off-label use) on
 the advice of a tertiary ADHD service. Note that an update from BSW lead mental health commissioner is expected to follow soon on the ongoing
 work around the local commissioning arrangements for patients with ADHD transitioning out of paediatric services and patients seen by private
 providers.
- **NEW BSW SCA for Stiripentol for Dravet Syndrome in children from 3yrs to adulthood.** Used in line with NICE NG217 and on the advice of a tertiary epilepsy service. Note that BSW APC recognises stiripentol is an expensive treatment, but patient numbers are expected to be extremely low.
 - **UPDATED BSW HRT Formulary treatment options and pathway.** Update includes information on National HRT pre-payment certificate and updated sections on off-license prescribing and useful links.
- **UPDATED Management of Infection Guidance for primary care.** Full guidance and QRG for children amendments made to the Scarlet Fever penicillin allergy antibiotics choice and course duration as per CKS.
- UPDATED <u>SGLT2 Prescribing Information all indications</u>. Guidance updated to clarify dosing in renal impairment in line with manufacturers Summaries of Product Characteristics.
- UPDATED DOACs for DVT and PE in adults: local pathways and prescribing criteria. Updated with clearer introductory statement
 reminding prescribers that edoxaban should NOT be used as a first line treatment for VTE. Also includes updated contact details for specialist
 teams and links to local hospital treatment pathways.
- UPDATED BSW Sharps bin guidance. Updated to include CGM consumables.

Other amendments to BSWformulary

- Sunsense Ultra range discontinued Formulary (bswformulary.nhs.uk)
- Fluocinolone acetonide 0.025% with clioquinol 3% (Synalar C®) discontinued Formulary (bswformulary.nhs.uk)
- Dithranol (Dithrocream®) range discontinued Formulary (bswformulary.nhs.uk)
- DMSO dimethyl sulphoxide bladder installation moved to non-formulary, no longer used locally. Sodium chondroitin bladder instillation (Uracyst®) discontinued Formulary (bswformulary.nhs.uk)
- Pholcodine-containing cough/cold medicines. Moved to non-formulary following withdrawal from UK market <u>Formulary (bswformulary.nhs.uk)</u>

EEEE Drug Switch of the Month -- Fostair pMDI (Beclometasone/formeterol) 100/6 & 200/6 to Luforbec pMDI 100/6 & 200/6

Prescribing Beclometasone/formeterol (Fostair) pMDI as the branded generic **Luforbec pMDI** could make just over a 30% saving! It is now BSW's **first choice** ICS/LABA **pMDI** for asthma and COPD and **where clinically appropriate** BSW supports the switching of new and existing Fostair **pMDI** patients to **Luforbec pMDI**. (Please remember that the **200/6 strength is licensed for asthma only** and **not COPD**. Please **DO NOT** switch patients using Fostair Nexthaler as that is a different device!).

Plus, as an added bonus it is certified carbon neutral by offsetting.

Remember to complete and submit the cost savings recording template to bswicb.prescribing@nhs.net

Did you know? SPS resources

Using bisphosphonates with proton pump inhibitors (PPIs) (Published 4 April 2023)

Although no interaction between bisphosphonates and PPIs is documented, the increased **risk of fractures** when given together should be reviewed and managed.

To sign up for weekly SPS updates such as this register here and tick box to receive updates, including regular newsletters.

FREE webinar: Audits as an antimicrobial stewardship tool

Join TARGET and RCGP for a free webinar. Register here. When? Thursday 18th May 2023, 18:30-19:30, Online

This webinar will cover:

- Using audits as part of a wider action plan to support positive change, increase adherence to guidelines and reduce inappropriate antibiotic
 prescribing
- Audits help identify areas for improvement and areas to celebrate
- Example of carrying out an antibiotic audit using a TARGET audit template

Who is it for?

Primary care medical practitioners, including, but not limited to:

- GPs
- Nurses
- Clinical/ practice pharmacists
- Medicines optimisation teams

Ophthalmic Drug Shortages

Ophthalmology colleagues have alerted us to increasing enquiries from primary care where patients are experiencing difficulties in obtaining certain ophthalmic drugs, including Monopost® (preservative free latanoprost). As an interim measure, local specialists consider there is very low risk in switching to an alternative preservative free prostaglandin analogue for one month, as suggested in the RCOPhth college advice here Drugs Shortages | The Royal College of Ophthalmologists (rcophth.ac.uk)

BSW medicines Optimisation team support primary care to make this change as an interim measure to avoid treatment delays. If the patient specifically objects/ rejects the alternative, advice should be sought from a glaucoma consultant on alternative *treatment options*.

Medicines Optimisation website
Updated documents

OTC Hay fever – patient advice <u>OTC-Hay-Fever-</u>patient-advice-leaflet


BSW Prescribing 2023-24 Savings Recommendations Prescribe Well – Spend Less (April 2023)<u>Prescribe-Well-Spend-Less-document</u> (April 2023)

Delivering a net zero NHS-

Greener NHS As the NHS works towards reaching the net zero ambition, there are a few initiatives that we wanted to draw your attention to:

- <u>PenCycle</u> prefilled insulin pen recycling scheme available to set up in pharmacies.
- TerraCycle offer a variety of recycling boxes and waste collection programmes, including PPE recycling.
- Avon Needs Trees tree planting days available in the local area.
- Superdrug blister pack recycling.
- Chiesi toolkit for setting up an inhaler recycling scheme (following 'Take AIR' pilot).
- Environmentally Sustainable Healthcare e-learning.
- The PrescQIPP work plan for 2023-25 includes a focus on sustainability in medicines optimisation.
- The Greener NHS Bulletin is available for anyone that would like to know more about the progress being made towards net zero.
- Further resources are available from the RCGP and Centre for Sustainable Healthcare.
- Chiesi offer free inhaler training, as well as various resources on <u>Chiesi air</u> and <u>The Lung Letters</u> websites, which may help to promote inhaler compliance.


Localisation of Ardens Templates



We have reccently started the process of localising some of the Arden formulary templates, so they more closely reflect our <u>BSW Formulary</u>. This will take some time and there's no time frame for when this work will be completed. The overall aim is to localise all the Ardens formulary templates. From the example below you can see that the nonformulary DPP-4 Inhibitors have been 'greyed' out so its clearer on which are our formulary options.

In the event that you need to prescribe a non-formulary option, remember it is possible to override the formulary by ticking the **highlighted box** on any formulary template.

BSW ICB Anticholinergic Burden Score Calculator



You may be aware that in 2022, the BSW ICB Medicines Optimisation team published an **anticholinergic burden (ACB)** score calculator in SystmOne. Use of this calculator was included in the 2022/23 Prescribing Incentive Scheme.

Ardens have recently published their own Anticholinergic Cognitive Burden Scale template, with similar functionality to the BSW ICB version, enabling users to calculate and record a patient's ACB score:

Action - Now the Ardens version is available, the BSW ICB ACB score calculator will be retired on 31st May 2023 and will not be available to practices after this date.

Please **update** your F12 launcher menu, toolbar icons and any other shortcuts to use the new Ardens template.

For information - Update on the funding of Inclisiran (Legvio®)

NHS E has updated the reimbursement for Inclisiran , full details can be found here

See section 2.3 -Inclisiran is available in general practice as a personally administered item reimbursed via an FP10 prescription and is listed in the Drug Tariff (Part VIIIC) at a Reimbursed Amount of £55 (£50 from 01 April 2023) per injection (the £45 Nominal Charge identified at 2.2 plus £10 (£5 from 01 April 2023)). BSW ICB updated guidance for Primary Care can be found here

This newsletter represents what is known at the time of writing so information may be subsequently superseded. Please contact the Medicines Optimisation Teams with comments/feedback or information for inclusion. This newsletter is aimed at healthcare professionals working within BSW.